98% Injectable Polypeptide Hormones CAS 16941-32-5 Vapreotide Acetate For Treating Esophageal Variceal Bleeding

· Vapreotide Acetate

· Sequence: D-Phe-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2

· Alias: Sanvar, RC-160; VAPREOTIDE; D-PHE-CYS-TYR-D-TRP-LYS-VAL-CYS-TRP-NH2; Octastatin;

· FCYWKVCW-NH2; D-Phe-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Trp-NH2;

· Cas No. : 103222-11-3

· Molecular Formula: C57H70N12O9S2

· Molecular Weight: 1131.40

· Purity (HPLC): 98.0%

· Appearance: White powder

· Single Impurity(HPLC): 1.0%

· Amino Acid Composition: 10% of theoretical

· Peptide Content(N%): 80%(by %N)

· Water Content(Karl Fischer): 6.0%

· Acetate Content(HPIC): 15.0%

· Mass Balance: 95.0~105.0%

· Grade : Pharmaceutical Grade

· Storage: Closed, below 2 ~ 8℃ preservation

· Usage : The drug can be used for treatment of early acute esophageal variceal bleeding (EVB) and endoscopic interventional therapy before hemostasis, can also be bleeding within 5 d lens for the treatment and prevention of recurrence after endoscopic. Vapreotide acetate will be the only approved treatment for esophageal variceal bleeding in the United States.

Description

Variceal bleeding is a life-threatening complication of portal hypertension. The recommended treatment includes the early administration of a vasoactive drug. Vapreotide is a somatostatin analogue with a different receptor affinity to octreotide. It decreases portal pressure and blood flow of collateral circulation in rats with cirrhosis. The pivotal study of early administration of vapreotide in patients with cirrhosis and variceal bleeding has shown a significant improvement in bleeding control and, in the subset of patients with significant bleeding, a significant reduction in mortality. In addition, a meta-analysis of four randomized studies has shown a significant improvement in bleeding control. Vapreotide administrated via the intravenous route is simple to use, with practically no contraindications and few, usually minor, side effects.

Application

The immediate release formulation of Sanvar, a somatostatin analogue, is used in the treatment of acute esophageal variceal bleeding (EVB).

Sanvar is used prior to endoscopic intervention to control haemorrhage and prevent re-bleeding during the critical five days following the onset of bleeding. EVB is a life threatening condition and the mortality rate is high (about 15% to 25%) in the first six weeks following the haemorrhage. EVB is the cause of about 70% of gastro-intestinal bleeding in patients suffering from liver cirrhosis.

Sanvar (vapreotide acetate) is a synthetic octapeptide analogue of the naturally-occurring somatostatin hormone. It has similar pharmacological properties to native somatostatin, but exhibits a longer duration of action. It is the only somatostatin analogue to have demonstrated statistically significant benefits in the early treatment of EVB in association with endoscopic therapy, in a placebo-controlled clinical study (Calès et al. New England Journal of Medicine, 2001). Control of bleeding with survival at five days was achieved more often with Sanvar (p=0.021) than with placebo. Additional Phase III trials have been completed in Europe in this indication. Sanvar can be stored at room temperature, an advantage over other products requiring refrigeration, allowing immediate administration, a key benefit in a life-threatening situation. The product has been granted orphan drug status in the U. S., where there is currently no FDA approved treatment for this indication.

Specifications

Product name	Vapreotide Acetate
Appearance	White Powder
Assay	98%
Molecular formula	C57H70N12O9S2
Molecular weight	1131.37
Package	2mg/vial or as your request
Shipping	Fast and secure shipping by DHL, EMS, UPS, TNT, FedEx..
Shipping leading time	Within 12 hours after receiving the payment
Payment Terms	Western Union, Money Gram , T/T
Price	Negotiable

Product list

Product Name	CAS NO.
Lypressin	50-57-7
Melanotan II	121062-08-6
Nesiritide acetate	114471-18-0
Octreotide acetate	83150-76-9
GRF (1-44) (HUMAN)	83930-13-6
Oxtocin	50-56-6
Ornipressin	3397-23-7
Pramlintide acetate	196078-30-5
ARG-LYS-GLU-VAL-TYR ACETATE SALT	105184-37-0
Secretin	17034-35-4
Sermorelin	86168-78-7
15-28-Somatostatin-28	38916-34-6
Teriparatide acetate	52232-67-4
Cosyntropin	16960-16-0
VAPREOTIDE	103222-11-3
N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin	14636-12-5
Thymosin alpha 1	62304-98-7
Thymosin beta 4 acetate	77591-33-4
Triptorelin	57773-63-4
Ziconotide acetate	107452-89-1